A Study Evaluating the Safety Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

  • STATUS
    Recruiting
  • End date
    Jun 30, 2023
  • participants needed
    80
  • sponsor
    Avacta Life Sciences Ltd
Updated on 31 July 2021
platelet count
cancer
gilbert's syndrome
doxorubicin
kidney function tests
neutrophil count
thromboplastin
neuropathy
cancer chemotherapy
alopecia
bladder tumor
kidney function test
soft tissue sarcoma

Summary

This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose will be assessed in one to three tumour types.

Description

This study is a first-in-human (FIH), Phase 1, open-label, multicentre, dose-escalation study investigating AVA6000 monotherapy administered intravenously (IV) in patients with locally advanced (unresectable) and/or metastatic solid tumours.

The study will be conducted in two parts: Phase 1a (Dose Escalation) and Phase 1b (Dose Expansion):

Phase 1a (Dose Escalation): The dose-escalation phase is designed to evaluate the safety, tolerability and MTD and/or RP2D of AVA6000, administered as monotherapy

Phase 1b (Dose Expansion): The dose-expansion phase will comprise 1 to 3 expansion arms in specific tumour types to evaluate the safety and tolerability of AVA6000 at the MTD or RP2D when administered as monotherapy. The tumour types to be explored in Phase 1b, will be determined based on evaluation of the Phase 1a data and the protocol will be amended accordingly.

Details
Condition Pancreatic Cancer, Non-Small Cell Lung Cancer, urinary tract neoplasm, Ovarian disorder, Colorectal Cancer, Connective and Soft Tissue Neoplasm, Rectal disorder, Pancreatic disorder, bladder cancer, bladder disorder, Breast Cancer, Ovarian Cancer, Neoplasm of unspecified nature of digestive system, Sarcoma, head and neck cancer, Breast Cancer Diagnosis, Bladder Carcinoma, breast carcinoma, colorectal neoplasm, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, carcinoma of the bladder, sarcomas, soft tissue sarcomas, cancer, breast, colorectal cancers, nsclc, cancer of the head and neck, cancer of the pancreas, ovarian tumors, pancreatic cancers, cancer, pancreatic, cancer, colorectal, colorectal tumor, tumors, colorectal, bladder tumor
Treatment AVA6000
Clinical Study IdentifierNCT04969835
SponsorAvacta Life Sciences Ltd
Last Modified on31 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Willing and able to give written informed consent
Male or female patients, 18 years of age
Histological or cytological confirmation of a locally advanced (unresectable) and/or metastatic pancreatic, CRC, NSCLC, SCCHN, ovarian, breast, soft tissue sarcoma and bladder cancer, who have either relapsed or progressed on SoC treatment or are intolerant or nonamenable to SoC treatment
In Phase 1b part of the study only: At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as 10mm in the largest diameter (except lymph nodes, which must have a short axis 15 mm) with CT or MRI scan and that is suitable for accurate repeated measurements
Life expectancy of greater than 12 weeks, in the opinion of the investigator
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Recovered from all acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure (must have resolved to CTCAE grade 1 or returned to baseline, except alopecia and peripheral neuropathy, which can be up to CTCAE grade 2)
Adequate haematological function (applies only to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)
Neutrophil count of 1.5 10^9 cells/L
Haemoglobin 9g/dL (with or without transfusion support)
Platelet count of 75,000/L (without transfusion within 2 weeks prior to Cycle 1, Day 1)
International normalised ratio (INR) and activated partial thromboplastin time (aPTT) 1.5 times the upper limit of normal (ULN)
Adequate liver function
Total bilirubin 1.5 ULN (in patients with Gilbert's Syndrome, <3 ULN is allowed)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 ULN (in patients with liver metastases, <5 ULN is allowed)
Alkaline phosphatase (ALP) <5 ULN (patients with documented liver or bone metastases only)
Adequate renal function
Serum creatinine 1.5 ULN (in patients for whom, in the Investigator's judgment, serum creatinine levels do not adequately reflect renal function, creatinine clearance by Cockcroft-Gale formula 50 mL/min may be used)
Women of childbearing potential (WOCBP) and women who have 2 years amenorrhea after start of menopause: has a negative serum pregnancy test within 7 days prior to Cycle 1, Day 1
Contraception requirements
Female patients of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method (Pearl Index failure rate <1% per year) during the treatment period and for at least 6 months after the last dose of study drug
Male patients with female partners of childbearing potential must agree to use 2 acceptable methods of contraception (Pearl Index failure rate <1% per year), including a barrier method (with or without spermicide) during the treatment period and for at least 6 months after the last dose of study drug

Exclusion Criteria

Received trastuzumab within 7 months of the planned Cycle 1, Day 1 AVA6000 infusion
Received a prior total cumulative anthracycline dose of >350mg/m^2 doxorubicin hydrochloride (or equivalent anthracycline dose)
Clinically significant or untreated central nervous system (CNS) metastases requiring treatment, as determined by the Investigator
Has leptomeningeal disease
Any history of an active (requiring treatment) other malignancy (except any in-situ carcinoma, non-melanoma skin carcinoma and early prostate cancer with a normal PSA) within 2 years of study entry
Has a significant, uncontrolled, concomitant disease that could affect compliance with the protocol
Has uncontrolled hypertension (systolic blood pressure [SBP] >150 mmHg and/or diastolic [DBP] >100 mm Hg), unstable angina, congestive heart failure (New York Heart Association (NYHA) Class >II), left ventricular ejection fraction (LVEF) <55% or the low limit of institutional normal limit (whichever is lower) by echocardiogram (ECHO), serious cardiac arrhythmia requiring treatment (exceptions include atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months prior to Cycle 1, Day 1; history of uncontrolled cardiovascular disease or high-sensitivity troponin above normal at baseline
Screening baseline mean QTcF interval (Fridericia's) of >470 msec, obtained from 3 electrocardiograms (ECGs). Has any clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250msec). Has any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, known family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval, a baseline resting bradycardia <45 beats/min or a baseline resting tachycardia of >100 beats/min
Known uncontrolled HIV infection
Active hepatitis B (HBV) or hepatitis C (HCV) infection
Positive hepatitis B surface antigen (HBsAG) test at Screening. Patients with a past or resolved HBV infection (defined as having a negative HBsAG test and a positive antibody to hepatitis B core antigen [antiHBc] antibody test) are eligible
Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
Severe infection(requiring IV treatment)within 21 days prior to Cycle 1, Day 1 including, but not limited to, hospitalisation for complications of infection, bacteraemia, or severe pneumonia
Any other clinically significant active disease, metabolic dysfunction, physical examination finding, clinical laboratory finding, or reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drugin the opinion of the investigator
Major surgery within 21 days prior to Cycle 1, Day 1 (excluding biopsies) or anticipates the need for major surgery during study treatment
Has dementia or altered mental status that in the opinion of the investigator would preclude providing informed consent
Pregnant or breastfeeding woman
Known hypersensitivity to any of the components of AVA6000 or any excipient related to the product
Received prior investigational therapy (defined as a treatment for which there is no Regulatory Authority-approved indication) within 21 or 42 days of Cycle 1 Day 1, for small molecule and biologic investigational therapies, respectively
Received any approved anticancer therapy, including chemotherapy or hormonal therapy, within 28 days prior to Cycle 1, Day 1, with the following exceptions
Hormone-replacement therapy or oral contraceptives
Tyrosine kinase inhibitors (TKIs) that have been discontinued more than 7 days prior to Cycle1, Day 1
Is planned for on study treatment or has received within 21 days prior to Cycle 1, Day
St John's Wort, any strong inhibitor or inducer of CYP3A4, CYP2D6, narrow therapeutic index CYP1A2, CYP2B6, or P-glycoprotein (PGP) or any moderate OATP1B3 inhibitor (will include statins)
Received systemic immunosuppressive medication (for any indication) at doses of >10mg prednisolone (or equivalent) within 28 days prior to Cycle 1, Day 1
Received radiotherapy within 28 days prior to Cycle 1, Day 1, except for limited field palliative radiotherapy. Patients who have received prior or concomitant radiotherapy to the mediastinal area are also excluded
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note